Cancer Institute

  • Gene L. Bidwell III

    bidwell_gene.jpgAssociate Professor
    Molecular Cancer Therapeutics
    PhD., Biochemistry, 2007, University of Mississippi Medical Center, Jackson, MS
    Postdoctoral Fellowship, 2007-10, University of Mississippi Medical Center, Jackson, MS

    Contact information
    Department of Neurology
    2500 N State St., Room N321-2
    Jackson, MS 39216
    Phone: (601) 984-6787
    E-mail: gbidwell@umc.edu

    Research interests

    • Targeted drug delivery
    • Therapeutic peptides
    • Breast cancer, glioblastoma, pregnancy

    Research synopsis

    My research interests include targeted drug delivery, therapeutic peptides, and protein-based therapeutics.  My background and training included the development of stimulus-responsive drug carriers for targeting drugs to solid tumors.  We utilized a thermally responsive carrier to target therapeutic peptides and small molecule chemotherapeutics to tumor sites using focused heating.  My current research interests include engineering protein carriers for delivery of peptide and protein-based therapeutics in several disease models.

    One of our current areas of focus is drug delivery during pregnancy.  We are developing carriers that can be fused to therapeutic agents, including chemotherapeutics, peptides, and proteins, that prevent them from crossing the placenta and reaching the baby.  Our goal is to develop a means to treat disorders of pregnancy (such as preeclampsia), or to deliver drugs currently unsafe for use during pregnancy, to pregnant patients without risking harm to the developing fetus from drug exposure.

    A second area of interest in my lab is delivery of neurotrophic growth factors to the brain (via intranasal administration or direct focal injection) for therapy of neurological disorders.  We are currently evaluating the delivery of protein carrier-fused growth factors for therapy of neurodegenerative disorders.  Fusion of growth factors as a chimera with this protein carrier allows us to easily purify the agents after recombinant expression and stabilizes them for use in vivo.

    Our lab also has an interest in therapeutic angiogenesis for kidney disease.  We are examining the use of carrier-fused, kidney-targeted growth factors for protection or regeneration of renal vasculature in the context of renal artery stenosis and chronic kidney disease.

    Another area of focus in our lab is developing a drug delivery system for administering therapeutics to the eye.  We are working to create anti-angiogenic and anti-microbial agents that have corneal penetrating capability to treat ocular disorders such as corneal neovascularization and bacterial keratitis.

    Recent accomplishments and honors

    • 2011 - Department of Defense Breast Cancer Research Program Era of Hope Conference Distinguished Postdoctoral Poster Award
    • 2010 - American Association for Cancer Research - Sanofi-Aventis Scholar-in-training Award
    • 2009 - University of Mississippi Medical Center Excellence in Research Award - Bronze Medal

    Selected publications

    • Renal Therapeutic Angiogenesis Using a Bioengineered Polymer-Stabilized Vascular Endothelial Growth Factor Construct. Chade AR, Tullos NA, Harvey TW, Mahdi F, Bidwell GL . J Am Soc Nephrol. 2016 Jun;27(6):1741-52. doi: 10.1681/ASN.2015040346. Epub 2015 Nov 5. PMID:26541349
    • Therapeutic Angiogenesis by VEGF Supplementation for Treatment of Renal Disease, Logue, O. C., McGowan, J. W. D., George, E. M., and Bidwell, G. L. III.  June 29, Epub ahead of print, Current Opinion in Nephrology and Hypertension, 2016
    • Corneal Penetrating Elastin-Like Polypeptide Carriers. George EM, Mahdi F, Logue OC, Robinson GG, Bidwell GL 3rd.  J Ocul Pharmacol Ther. 2016 Apr;32(3):163-71. doi: 10.1089/jop.2015.0082. Epub 2015 Dec 16. PMID:26672799
    • Placental origins of adverse pregnancy outcomes: potential molecular targets: an Executive Workshop Summary of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Ilekis JV, Tsilou E, Fisher S, Abrahams VM, Soares MJ, Cross JC, Zamudio S, Illsley NP, Myatt L, Colvis C, Costantine MM, Haas DM, Sadovsky Y, Weiner C, Rytting E, Bidwell G. Am J Obstet Gynecol. 2016 Mar 10. pii: S0002-9378(16)00447-6. doi: 10.1016/j.ajog.2016.03.001. PMID: 26972897
    • Growth Factor Purification and Delivery Systems (PADS) for Therapeutic Angiogenesis. George, E. M., Liu, H., Robinson, G., Mahdi, F., Perkins, E. P., and Bidwell, G. L. III,Vascular Cell, 7:1, Jan. 24, 2015.  PMID: 27367910
    • Nitroreductase-triggered activation of a novel caged fluorescent probe obtained from methylene blue.Bae J, McNamara LE, Nael MA, Mahdi F, Doerksen RJ, Bidwell GL 3rd, Hammer NI, Jo S. Chem Commun (Camb). 2015 Aug 18;51(64):12787-90. doi: 10.1039/c5cc03824c. PMID:26165999
    • Challenges and New Strategies for Therapeutic Peptide Delivery to the Central Nervous System. McGowan, J. W. D., Bidwell, G. L. III, and Vig, P. J. S.   Therapeutic Delivery, July, 2015
    • [276-POS]: Maternally sequestered polypeptide-based therapeutics to treat preeclampsia. Bidwell GL 3rd1, M George E1. Pregnancy Hypertens. 2015 Jan;5(1):138. doi: 10.1016/j.preghy.2014.10.282. Epub 2015 Feb 23.
    • Growth factor purification and delivery systems (PADS) for therapeutic angiogenesis. George EM1, Liu H2, Robinson GG2, Mahdi F2, Perkins E3, Bidwell GL 3rd4. Vasc Cell. 2015 Jan 24;7(1):1. doi: 10.1186/s13221-014-0026-3. eCollection 2015.
    • Maternally Sequestered Therapeutic Polypeptides - A New Approach for the Management of Preeclampsia.  Bidwell, G. L. III and George, E. M  Frontiers in Pharmacology, 5;5:201, 2014.